Management of a hypertensive ulcer with an epidermal growth factor-based formulation.
This rare ulcer was treated with a human recombinant epidermal growth factor-based formulation and antihypertensive drugs. Full granulation was achieved in 49 days and complete wound closure in 79 days. No adverse events were reported.
Hernández-Cañete
C
C
canete@trocha.cav.sld.cu
Betancourt
B Y
BY
D000368:Aged; D002626:Chemistry, Pharmaceutical; D003646:Debridement; D004815:Epidermal Growth Factor / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006097:Granulation Tissue / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007871:Leg Ulcer / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D035583:Rare Diseases / Q000188:drug therapy; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D004815:Epidermal Growth Factor